

Fax Referral To: 1-800-323-2445 Phone: 1-800-237-2767 Email Referral To: Customer.ServiceFax@CVSHealth.com Coram National Call Center Fax: 1-866-843-3221



1 PATIENT INFORMATION (Complete o		ubmitting a Refe	Trat
Patient Name:			Gender: 🗌 Male 🔲 Female
Address:		DOB _City, State, ZIP Code:	
Preferred Contact Methods: Phone (to prima	rv # provided below)	_Orty, State, Zir Code] Text (to cell # provided	below) Fmail (to email provided below)
Note: Carrier charges may apply. By providing th	e phone number(s) and	email address above, voi	u are consenting to receive automated calls
emails and/or text messages from CVS Specialty			
frequency varies. If unable to contact via text or e			
Primary Phone:			
			ary Language:
Parent/Caregiver/Legal Guardian Name (Last, F			
2 PRESCRIBER INFORMATION			
Prescriber's Name:		State License #	
NPI #: DEA #: Gr	oup or Hospital:	0tato 21001130 11	
Address: Fax	Contact Person:	Contact's	Phone:
INSURANCE INFORMATION Please			
Is the Patient Insured? ☐ Yes ☐ No Is the			
Policy Holder's Name: Medical Insurance:	Policy F	Holder's DOB:	Relationship to Patient:
Prescription Insurance:		Prescription Plan	1 Telephone:
Policy ID:(aroup #:	RX BIN #:	RX PCN #:
Check box if patient is enrolled in manufact		e If yes, please provide	ID#
4 DIAGNOSIS AND CLINICAL INFOR	MATION		
Needs by Date:		Ship to: Patient	Office Other:
Diagnosis (ICD-10):			
M06.9 Rheumatoid Arthritis, Unspecif	ied		
M45.9 Non-Radiographic Axial Spond		A)	
M45.A0 Ankylosing Spondylitis of Uns			
L40.50 Arthropathic Psoriasis, Unspec		110	
	JIIIGU		
L40.59 Other Psoriatic Arthropathy		:r: 1 0::	
M08.00 Unspecified Juvenile Rheuma		specified Site	
M08.90 Polyarticular Juvenile Idiopat			
M08.20 Systemic Juvenile Idiopathic	Arthritis (SJIA)		
M31.6 Giant Cell Arteritis (GCA)			
Other Code: Description			
Patient Clinical Information:			
Allergies:			
Prior therapy, treatment dates, and reason(s)	for discontinuation:		
Treatment status: New to therapy Cor	tinuation of therapy; c	 late of last treatment	_// Needs by date:
 Weight:lb/kg Height:	In/cm	TB Test Result:	Date:
Nursing and Administration:			
First dose administration of monoclonal antibe	ndies (mABs) should h	ne administered in a con	trolled setting (may vary depending upon
medication specific policy).	sales (IIII 126) sileata s		trouble detailing (may vary depending apon
For Remicade/Remicade Biosimilars, the fir	st dose must he adm	inistered in a controlled	d setting.
Specialty pharmacy to coordinate home healt			
Site of Care: Home Infusion* Coram		- <u> </u>	
*Home Infusion/Coram AIS: Diluents, Flushes	=		
**Prescriber's Office/Other Infusion Clinic: Dr		_	

	Please Con	nplete Patient, Prescriber	and Patient Clinical Information	
	Patient DOB: Patient Phone:			
Patient Clinical Ir			Prescriber Phone:	
Margias.				
Neight:	lb/ka Heia	nt: In/cm	TB Test Result:	Date:
PRESCRIPTI	ON INFORMATIO	N		
	STRENGTH		E & DIRECTIONS	QUANTITY/REFILLS
Actemra	80 mg/4 mL 200 mg/10 mL 400 mg/20 mL	Induction Dose: Infuse 4 Infuse Dose: Infuse Other:		Quantity: Refills:
☐ Avsola	100 mg vial	Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other:		Quantity: # of 100 mg vial(s) Refills:
☐ Inflectra ☐ Infliximab	100 mg vial	Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other:		Quantity: # of 100 mg vial(s) Refills:
Patient is interested in		STAMP SIGNATURE NOT		vided as needed for administratio
	PRESCRIBER SI	GNATURE REQUIRED (S	TAMP SIGNATURE NOT ALLOW	ED)
"Dispense As Written" DAW / May Not Substi		/ Do Not Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible	
•	nature:	Date:	Prescriber's Signature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

ationt Name:		lete Patient, Prescriber and Patient Clinical Information	
		Patient DOB: Patient Phone:	
	· 9:		
atient Clinical			
eight:	lb/kg Height:	In/cm TB Test Result:	Date:
	TION INFORMATION		
	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Orencia	250 mg vial	☐ Infuse mg at weeks 0, 2 and 4, then every 4 weeks thereafter. ☐ Other:	Quantity: Refills:
Remicade Renflexis	100 mg vial	Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other:mg) every 4, 6 or 8 weeks (circle one)	Quantity: # of 100 mg vial(s) Refills:
Riabni Rituxan Ruxience	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial	☐ Infuse two doses of 1000 mg separated by 2 weeks. ☐ Other:	Quantity: Refills:
Simponi ARIA	50 mg/4 mL in a single use vial	Adult patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Infuse 2 mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter. Pediatric patients with polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter Other:	Quantity: # of 50 mg vial Refills:
Patient is interested	in patient support programs PRESCRIBER SIG	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits prov NATURE REQUIRED (STAMP SIGNATURE NOT ALLOW	
"Dispense As Writte DAW / May Not Sub Prescriber's Si		o Not Substitute / No Substitution / May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

			nd Patient Clinical Information	
			Patient Phone:	
Patient Address:				
Prescriber Name	e:	P	rescriber Phone:	
Patient Clinical	Information:			
Allergies:				
			B Test Result:	Date:
PRESCRIP	TION INFORMATION			
MEDICATION	STRENGTH	DOS	E & DIRECTIONS	QUANTITY/REFILLS
Truxima	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial		O mg separated by 2 weeks	Quantity: Refills:
☐ Tyenne (tocilizumab-aazg) ☐ 80 mg/4 mL vial ☐ 200 mg/10 mL vial ☐ 400 mg/20 mL vial	RA Induction Dose: Infuseeeks	se 4 mg per kg (mg) IV every 4		
	weeks (doses exceeding 80 recommended)	nfuse 8 mg per kg (mg) IV every 4 00 mg per infusion are not	Quantity:	
	Giant Cell Arteritis Dose: Infuse 6 mg per kg (mg) IV every 4 weeks (doses exceeding 600 mg per infusion are not recommended)		4	
	☐ PJIA Dose (≥ 2 years old weighing < 30 kg): Infuse 10 mg per kg (mg) IV every 4 weeks		vials) vials) vials)	
	\square PJIA Dose (\geq 2 years old weighing \geq 30 kg): Infuse 8 mg per kg (\square mg) IV every 4 weeks		Refills:	
	SJIA Dose (> 2 years old weighing < 30 kg): Infuse 12 mg per kg (mg) IV every 2 weeks			
	SJIA Dose (\geq 2 years old weighing \geq 30 kg): Infuse 8 mg per kg (mg) IV every 2 weeks			
	Other:		_	
Other	Strength:			Quantity:Refills:
	6 PRESCRIBER SIG	NATURE REQUIRED (S	TAMP SIGNATURE NOT ALLO	WED)
DAW / May Not Sub	en" / Brand Medically Necessary / Destitute	o Not Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible	
Prescriber's Si	gnature:	Date:	Prescriber's Signature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Rheumatology IV Enrollment Form Nursing Orders

Patient Address:		Patient DOR ¹		
			Patient Phone: _	
Irogarihar Namas			receriber Dhone:	
Prescriber Name: Patient Clinical Informa		Pr	rescriber Phone:	
	tion:			
.llergies: Veight:	lh/ka Haiaht	In/om TE	B Test Result:	Doto:
DDECODIDATION IN	_tb/kg = neight.		rest result.	Date:
PRESCRIPTION	NFORMATION	**ITEMS BELOW THIS LINE WIL	L ONLY BE SENT FOR INFUSIONS DONE	
MEDICATION/SUPPLIES	ROUTE		NGTH/ DIRECTIONS	QUANTITY/REFILLS
Catheter: PIV PORT CVC/PICC	IV	maintain IV access and paten PIV: NS 5 mL (Heparin 10 units	s/mL 3-5 mL if multiple days) eparin 10 units/mL or 100 units/mL access PORT w/ huber needle	Quantity: Refills:
Hydration: ☐ NS ☐ D5W	IV	Pre:	☐Other: 000 mL ☐ Other: ☐Other:	Hydration max infusion rate mL/hr (Adult max rate 250 mL/hr unless otherwise indicated)
☐Epinephrine **nursing requires**	□ IM □ SC	☐ 1:1000, 0.3mg/0.3 mL (greater than 30 kg/66 lbs) ☐ 1:2000, 0.15mg/0.3 mL (15-30 kg/33-66 lbs) ☐ 1:1000, 0.1 mg/kg, Max 0.3mg (under 15kg) Mild-Moderate Reactions. May repeat in 3-5 minutes as needed for severe allergic reaction, also call 911		Quantity: Refills:
☐ Diphenhydramine Oral	PO	Premedication: 12.5 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg)		Quantity: Refills:
Diphenhydramine 50 mg/mL vial **nursing required**	☐ Slow IV	1 mg/kg (under 15 kg) 12.5 mg-50 mg (15-30 kg) 25 mg-50 mg (Over 30 kg) If mild/moderate reaction: may repeat in 3-5 minutes as needed (Adult max dose: 100 mg/day) If severe allergic reaction: call 911		Quantity: Refills:
☐ Flush Orders:	Peripheral Access Central Venous Access	☐ 10 mL NS post flush ☐ 50 mL NS post flush to clear medication from tubing (recommended if no post-hydration) ☐ Other:		Send quantity sufficient for medication days supply
Additional Medication:				
Patient is interested in patient sup		STAMP SIGNATURE NOT ALLOWED NATURE REQUIRED (ST	Ancillary supplies and kits TAMP SIGNATURE NOT ALLO	provided as needed for administrati
DAW / May Not Substitute		o Not Substitute / No Substitution / Date:	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.